Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs GSK plc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5, while GSK plc trades at $50.62 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none. Which is the better fit depends on your goals.
| BIL | GSK | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $61.18 |
52-Week Low | $91.27 | $38.22 |
Market Cap | — | $102.60B |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
